Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Cmpw Mandigers"'
Autor:
Ccd van der Rijt, Wmw Dercksen, Mjb Aarts, Yjl Kamm, Hwr Nortier, S. M. van Gastel, Alphons G.H. Kessels, Ljc van Warmerdam, Cmpw Mandigers, Manuela A. Joore, Vcg Tjan-Heijnen, Jacqueline M. Stouthard, F.P.J. Peters
Publikováno v:
Cancer Research. 70:P3-15
Background: In patients at risk of febrile neutropenia (FN), the highest incidence of FN is seen during the first chemotherapy cycles. This observation questions the effectiveness of continued G-CSF prophylaxis during later chemotherapy cycles. Metho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e0cb4b1ffebc98269b63124f9c2021a6
https://doi.org/10.1158/0008-5472.sabcs10-p3-15-01
https://doi.org/10.1158/0008-5472.sabcs10-p3-15-01
Publikováno v:
European Journal of Cancer. 29:S134
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2af6f6b9187e63143fcbdc9e9da56fbc
https://doi.org/10.1016/0959-8049(93)91357-q
https://doi.org/10.1016/0959-8049(93)91357-q
Autor:
Mandigers, C. M. P. W.1,2 c.mandigers@planet.nl, Verdonck, L. F.3, Meijerink, J. P. P.4,5, Dekker, A. W.3, Schattenberg, A. V. M. B.1, Raemaekers, J. M. M.1
Publikováno v:
Bone Marrow Transplantation. Dec2003, Vol. 32 Issue 12, p1159-1163. 5p. 1 Chart, 3 Graphs.
Autor:
van der Voort A; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands., Louis FM; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands., van Ramshorst MS; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands., Kessels R; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, Netherlands., Mandjes IA; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, Netherlands., Kemper I; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands., Agterof MJ; Department of Medical Oncology, St Antonius Hospital, Nieuwegein, Netherlands., van der Steeg WA; Department of Medical Oncology, Isala, Zwolle, Netherlands., Heijns JB; Department of Medical Oncology, Amphia, Breda, Netherlands., van Bekkum ML; Department of Medical Oncology, Reinier de Graaf Gasthuis, Delft, Netherlands., Siemerink EJ; Department of Medical Oncology, Ziekenhuisgroep Twente, Hengelo, Netherlands., Kuijer PM; Department of Medical Oncology, Spaarne Gasthuis Hoofdorp, Netherlands., Scholten A; Department of Radiation, Netherlands Cancer Institute, Amsterdam, Netherlands., Wesseling J; Division of Molecular Pathology and Department of Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Pathology, University Medical Centre, Leiden, Netherlands., Vrancken Peeters MTFD; Department of Surgery, Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Surgery, Amsterdam University Medical Centre, Amsterdam, Netherlands., Mann RM; Department of Radiology, Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Imaging, Radboud University Medical Center, Amsterdam, Netherlands., Sonke GS; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Amsterdam University Medical Centre, Amsterdam, Netherlands. Electronic address: g.sonke@nki.nl.
Publikováno v:
The Lancet. Oncology [Lancet Oncol] 2024 May; Vol. 25 (5), pp. 603-613. Date of Electronic Publication: 2024 Apr 05.